The ROE as of December 2024 (TTM) for Dyadic International, Inc. (DYAI) is -149.17%

According to Dyadic International, Inc.’s latest financial reports and current stock price. The company's current ROE is -149.17%. This represents a change of 297.08% compared to the average of -37.57% of the last 4 quarters.

Dyadic International, Inc. (DYAI) Historical ROE (quarterly & annually)

How has DYAI ROE performed in the past?

The mean historical ROE of Dyadic International, Inc. over the last ten years is 0.29%. The current -149.17% ROE has changed -50840.82% with respect to the historical average. Over the past ten years (40 quarters), DYAI's ROE was at its highest in in the December 2015 quarter at 87.65%. The ROE was at its lowest in in the September 2015 quarter at -303.09%.

Dyadic International, Inc. (DYAI) ROE by Quarter and Year

Discovering the peaks and valleys of Dyadic International, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Dyadic International, Inc. (DYAI) Average ROE

How has DYAI ROE performed in the past?

The current ROE of Dyadic International, Inc. (DYAI) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Dyadic International, Inc. (DYAI) ROE vs. Peers

How is DYAI’s ROE compared to its peers?

Dyadic International, Inc.’s ROE is greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Decibel Therapeutics, Inc. (-56.38%), greater than Celcuity Inc. (-62.66%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than AN2 Therapeutics, Inc. (-57.63%), less than Eliem Therapeutics, Inc. (0%), greater than HCW Biologics Inc. (-2516.87%), greater than Molecular Partners AG (-39.16%), greater than MediciNova, Inc. (-20.70%), less than Champions Oncology, Inc. (66.22%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than Forte Biosciences, Inc. (-151.43%), greater than DiaMedica Therapeutics Inc. (-43.68%), less than Kineta, Inc. (934.78%), greater than Kintara Therapeutics, Inc. (-454.05%),

Build a custom stock screener for Dyadic International, Inc. (DYAI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dyadic International, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dyadic International, Inc. (DYAI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dyadic International, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.